Physician profile
Muhammad Farooq
NPI 1467432120
$1,055.49
in general payments reported to CMS, 2019-2025
11 companies · $41.80 in 2025
The $41.80 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $545 · 2022: $211 · 2023: $114 · 2024: $143 · 2025: $41.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $299.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Medicine, INC. | $192.68 | 2021 | |
| Astellas Pharma US INC | $180.95 | 2021-2022 | |
| Genentech USA, INC. | $137.22 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $124.98 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $120.32 | 2021 | |
| Kite Pharma, INC. | $89.22 | 2023 | Yescarta |
| Actelion Pharmaceuticals US, INC. | $84.60 | 2024 | Uptravi, Opsumit |
| Gilead Sciences, INC. | $54.34 | 2024-2025 | Trodelvy |
| Janssen Biotech, INC. | $25.27 | 2023 | Darzalex |
| Amgen INC. | $24.79 | 2025 | Krystexxa |
| Abbott Laboratories | $21.12 | 2024 | Amplatzer Amulet |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Farooq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.